Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson Dr. Yusof interviews Dr. Robinson about abstract OP0013, presented at the virtual #EULAR2021 meeting. https://t.co/IPe6lMM7NQ

• https://bit.ly/3g8wMfj

Complements that are low in #SLE pregnancy have POORER fetal outcomes. What happens to C3 & C4 in pregnancy? They should ⬆️ by 28% C3, 11% C4 in 1st Trimester ⁦@RheumNow⁩ #EULAR2021 POS0103. So order C3&C4 early in pregnancy in SLE & follow! https://t.co/FpHHj74e43

Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 ⁦@RheumNow⁩ #EULAR2021 ⁦@eular_org⁩ https://t.co/8WCrt11ubV

Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq

“When patients present with LN, they already lost alot of nephrons!” - Prof F Houussiau on the importance of early aggressive Rx for LN #EULAR2021 @rheumnow

Patient with SLE says I am flaring BUT you say No! Just like in RA, there often is poor QoL. POS0101 Despite response to Rx SF36 shows less QoL vs pop’n. Need to look at what can be improved beyond active SLE #EULAR ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/C17FRTBsUq

OPO132: Dr. Werth presents Iberdomide targeting cereblon ligand on SLE skin. Iberdomide 0.45 mg QD showed improvement vs PBO for SCLE & CCLE, not seen for ACLE. Interesting new target, affects B cell and type 1 IFN pathways @Rheumnow #Eular2021 https://t.co/nuDM7h59MB

#EULAR2021 OP0133 retinal toxicity with HCQ use. ⬆️ risk: ⭐️Duration 10-14.9 yr (OR 5) ⭐️Duration >15 yr (OR 19) ⭐️Dose >7 mg/kg/d (OR 4.6) ⭐️Cum dose >2000 g Atherosclerosis, age >80 seen in multi-var analysis But didn't have HCQ levels to predict risk @MaxKonigMD @RheumNow https://t.co/DzWWm0U64L

Anifrolumab pooled TULIP-1&-2 data on rash and arthritis in SLE more effective in pts with high IFN signals (pts with low IFN may benefit, but they had less rash but more arthritis)- Dr. J Merrill #OP0131 #EULAR2021 @rheumnow

@KDAO2011 @RheumNow @LupusDocLim @Lupusdoc1 @LupusMD Check this! (top left corner) #HCQ #Lupus #EULAR2021 Link: https://t.co/RQcWoStJtP https://t.co/96l1FvYDQH

• SAGE Journals: Your gateway to world-class journal research